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Interventional cardiology is a very fast developing speciality
of cardiology, offering today a broad spectrum of therapies,
and still allowing for a close cooperation with cardiac sur-
geons. Recent developments in interventions are ongoing in
many fields and cover, for instance, the introduction of new
antiplatelet drugs and strategies of percutaneous coronary
interventions (PCI) in acute myocardial infarction [1], left
main and bifurcation stenting [2,3], percutaneous heart valve
therapy [4–6], as well as device closure of the left atrial
appendage [7]. This special issue of Cor et Vasa is therefore
focused on the novel or relatively novel methods or techni-
ques that have evolved recently and are practically used in
cardiac interventions. The issue was prepared by authors
from the Czech interventional and cardiosurgical centers.
Before we summmarize articles which are presented in this
issue, we would like to comment on some of the topics
mentioned above.New antiplatelet drugs and strategies of
percutaneous coronary interventions
Percutaneous coronary intervention is a well established
treatment in patients with myocardial infarction with ST-
segment elevations. The practice of using coronary stents,
antiplatelet thienopyridines and heparines as well as IIb/IIIa
inhibitors is well established, but several questions still
remain unanswered and lead to the introduction of several
new drugs which should prove beneficial: prasugrel [8], more
potent thienopyridine platelet inhibitor with rapid onset,
ticagrelor [9], a nontheinopyridine inhibitor of P2Y12 adeno-
sine phosphate receptor blocker, and bivalirudin—direct
thrombin inhibitor [10].Coronary interventions
Surgical approach to unprotected left main coronary artery
disease was regarded as the treatment of choice for many
years, but current experience from several registries and
clinical trials have made PCI an alternative revascularizationtherapy for such patients. When compared to surgery, the
only difference is the rate of repeat revascularization, other-
wise composite outcome of death, myocardial infarction and
stroke is similar in surgical as well as PCI approach [2]. Also
bifurcation lesions remain among challenging lesions for
PCI’s, proper classification like recently described and clini-
cally oriented DINO classification [3] is crucial for choosing
the right PCI techniques. The practical overview of Zelizko
et al. in this issue of Cor et Vasa very well demonstrate the
complexity of coronary bifurcations treatment as one of the
remaining challenges in interventional cardiology. More rele-
vant view on the coronary arteries and coronary circulation
can be obtained from two other articles. Concept of func-
tional revascularization described by Mates et al. seems to be
the most appropriate and clinically relevant approach to
revascularization in patients with stable or stabilized coron-
ary lesions. Fractional flow reserve measurement received
the strongest recommendation from European Society of
Cardiology (Class I, level of evidence A) for defining the
ischemic myocardium. Information coming from the optical
coherent tomography as the most precise method of mor-
phologic imaging, described in article of Kanovsky et al.
provides generally a broader understanding of coronary
artery disease as well as the results of coronary artery
stenting.Percutaneous heart valve therapy
Percutaneous heart valve therapy includes transcatheter
aortic valve implantation (TAVI) in patients with aortic
stenosis [4], mitral valve repair (MVR) in patients with mitral
regurgitation [5,6], as well as pulmonary valve implantation.
With more than 50,000 implantation worldwide, TAVI has
been shown to be a viable alternative to surgery for patients
with symptomatic severe aortic stenosis at high risk for open
heart surgery and details of PARTNER Trial have been dis-
cussed in the last issue of Cor et Vasa [11]. Czech TAVI Registry
follows almost all the TAVI procedures performed in the
Czech Republic since the beginning of the program. Design
of the Registry described in the article of Kala et al. was
established in collaboration with Carlo di Mario, the former
President of the European Association of PCI (EAPCI).
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The structural therapy for the left atrial appendage closure
has been developed and introduced to clinical practice
recently—the Watchman device was compared with war-
farin therapy in the PROTECT-AF Trial [7]. There was no
difference in the ischemic strokes rates in both groups and
long term follow-up will definitely show, whether beneficial
effect of device will continue because warfarin events are
likely to accumulate in longer time. Also in this first special
issue of Cor et Vasa, Stasek et al. discuss the therapeutic
options to prevent the risk of systemic embolization in
patients with chronic atrial fibrillation. Especially in
patients with contraindication to chronic anticoagulation
therapy left atrial appendage closure might be the therapy
of choice.Paravalvular leaks, hybrid revascularization, renal
denervation, aortic dissection
Other topics, which we present in this special issue of Cor et
Vasa include a manuscript from Branny et al. which focuses
on the paravalvulars leaks management from diagnosis to
interventional treatment; an article by Horak et al. which
provides us with the cardiologist view on hybrid revascular-
ization, i.e. the combined surgical and interventional therapy,
and a manuscript of Poloczek et al. which extends the insight
into the rather promising interventional therapy—renal
denervation in the treatment of resistant arterial hyperten-
sion. Finally, Nemec et al. provide us with a sophisticated and
interesting comparison of two therapeutic approaches to
acute aortic dissections. Less invasive aortic valve sparing
operation was associated with excellent results during mid-
term follow-up.Summary
In conclusion, we can hope that interventional cardiology
innovations will continue to evolve and new methods will
broaden the practice of current procedures, and will improve
all options of nonsurgical treatment available for our
patients. Some of them are presented in the upcoming
articles of Czech interventional cardiologists, who all use
those methods in their daily work achieving successes not
only in elective cases, but also in acute patients.r e f e r e n c e s
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